A similar enhancement of EDR, which is resistant to l‐NOARG and indomethacin, and a similar contribution of KCa3.1 and/or KCa2.3 to EDR were reported to occur in arteries from rats with obesity (Chadha et al., 2010; Climent et al., 2014), type 2 diabetes mellitus (Schach et al., 2014), and spontaneous hypertension (Giachini et al., 2009; Simonet et al., 2012). Here, KCNN3 is linked to hypertensive disorder.